Nephro Care India’s IPO will hit the market on June 28, 2024, and close on July 02, 2024. The Nephro Care India IPO GMP Kostak rate and subject to sauda updated as of today. The Nephro Care India IPO Grey Market Premium has started with high premium rates at this time, we need to wait for the rates to change with the market sentiment in a few days or to stabilize the rates. You can check Nephro Care India’s IPO subscription status here.
Nephro Care India Limited is a comprehensive treatment center located in Kolkata, offering a wide range of clinical and lifestyle solutions, as well as renal insufficiency treatment for patients. Currently, the hospital provides healthcare services to approximately 900 Chronic Kidney Disease patients every month. The hospital has 5 permanent doctors, 10 visiting consultants, and 70 experienced paramedical professionals.
Nephro Care India IPO Issue size of ₹41.26 Crores, in which Fresh Issue of ₹41.26 Crores and issue price band has been fixed at ₹85 to ₹90 Per Share. The Nephro Care India IPO is to be listed on July 05, 2024, on NSE, SME.
What is Nephro Care India IPO GMP Today?
■ The Nephro Care India IPO GMP Today Or Grey Market Premium is ₹230.
What is Nephro Care India IPO Kostak Rates Today?
■ The Nephro Care India IPO Kostak rate is ₹0.
What is Nephro Care India IPO Subject to Sauda Price Today?
■ The Nephro Care India IPO Subject to Sauda rates is ₹285,500.
Nephro Care India IPO Approximately Returns?
■ The Nephro Care India IPO’s approximate return is 320%, and it can also change according to the Market Sentiment.
Nephro Care India IPO GMP Live, Kostak, & Subject :
| Date | GMP | Kostak | Subject |
| 04 Jul 2024 | ₹230  | ₹0 | ₹285,500 |
| 03 Jul 2024 | ₹230  | ₹0 | ₹285,500 |
| 02 Jul 2024 | ₹180 | ₹0 | ₹218,500 |
| 01 Jul 2024 | ₹155 | ₹0 | ₹188500 |
| 30 Jun 2024 | ₹120 | ₹0 | ₹146000 |
| 29 Jun 2024 | ₹120 | ₹0 | ₹146000 |
| 28 Jun 2024 | ₹100 | ₹0 | ₹121500 |
| 27 Jun 2024 | ₹100 | ₹0 | ₹121500 |
| 26 Jun 2024 | ₹20 | ₹0 | ₹24500 |
IPO GMP Facts :
- The GMP is usually higher for IPOs of well-known companies with strong fundamentals.
- The GMP is also likely to be higher for IPOs that are heavily subscribed.
- It is important to do your own research before investing in an IPO, regardless of the GMP.
- The IPO GMP is estimated, considering market volatility, limited historical data, underwriting conditions, legal risks, and potential dilution.
IPO GMP Disclaimer :
- GMP is not an indicator of the final listing price: The GMP is just a reflection of the demand and supply of the IPO shares in the grey market. The final listing price will depend on a number of factors, including the overall market sentiment and the performance of the company in the post-IPO period.
- The GMP can be volatile: The GMP can fluctuate significantly in the days leading up to the IPO listing. This is due to the uncertainty surrounding the final listing price and the volatility of the stock market in general.
- There is no guarantee of profit: Even if the GMP is high, there is no guarantee that the IPO shares will list at a profit. The final listing price could be lower than the GMP, or the shares could even decline in value after listing.
- Investing in IPOs carries risks: IPOs are considered to be high-risk investments. There is always the possibility that the company could fail, or that the shares could be diluted in the future.
- Risk Factors: Identify and articulate the key risk factors that could impact the IPO GMP and subsequent trading of the company’s shares. These may include industry-specific risks, regulatory uncertainties, economic downturns, and competitive pressures.
| Nephro Care India IPO Details: Click Here Nephro Care India IPO Subscription: Click Here Nephro Care India IPO Allotment: Click Here Nephro Care India IPO Listing: Click Here |
All Nephro Care India IPO-related links are available here. If you want to know the details then click on the click here Link.
Disclaimer: STOCK MARKET INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME-RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.